Literature DB >> 9918823

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

H Tamamura1, Y Xu, T Hattori, X Zhang, R Arakaki, K Kanbara, A Omagari, A Otaka, T Ibuka, N Yamamoto, H Nakashima, N Fujii.   

Abstract

T22 ([Tyr5,12, Lys7]-polyphemusin II) is an 18-residue peptide amide, which has strong anti-HIV activity. T22 inhibits the T cell line-tropic (T-tropic) HIV-1 infection through its specific binding to a chemokine receptor CXCR4, which serves as a coreceptor for the entry of T-tropic HIV-1 strains. Herein, we report our finding of novel 14-residue CXCR4 inhibitors, T134 and T140, on the basis of the T22 structure. In the assays we examined, T140 showed the highest inhibitory activity against HIV-1 entry and the strongest inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 among all the CXCR4 inhibitors that have been reported up to now.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9918823     DOI: 10.1006/bbrc.1998.9871

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  62 in total

Review 1.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

2.  The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Authors:  Stéphanie Gravel; Camille Malouf; Philip E Boulais; Yamina A Berchiche; Shinya Oishi; Nobutaka Fujii; Richard Leduc; Daniel Sinnett; Nikolaus Heveker
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

3.  Stromal-derived factor-1 (CXCL12) regulates laminar position of Cajal-Retzius cells in normal and dysplastic brains.

Authors:  Mercedes F Paredes; Guangnan Li; Omri Berger; Scott C Baraban; Samuel J Pleasure
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

Review 4.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 5.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 6.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

7.  Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.

Authors:  Royce A Wilkinson; Seth H Pincus; Kejing Song; Joyce B Shepard; Alan J Weaver; Mohamed E Labib; Martin Teintze
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823

8.  A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

Authors:  Sandra Claes; Thomas D'huys; Anneleen Van Hout; Dominique Schols; Tom Van Loy
Journal:  J Vis Exp       Date:  2018-02-20       Impact factor: 1.355

9.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Wataru Nomura; Nobutaka Fujii
Journal:  Perspect Medicin Chem       Date:  2008-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.